Roche insists amylin obesity drug still valuable for patients who ‘don’t want side effects’
BioSpace
Roche and Zealand Pharma announced last month that their amylin analog petrelintide elicited a 9% placebo-controlled weight reduction at 42 weeks--falling far below analyst and investor expectations.
pharminent
April 23, 2026 (Last updated: April 23, 2026)
BioSpace
Roche and Zealand Pharma announced last month that their amylin analog petrelintide elicited a 9% placebo-controlled weight reduction at 42 weeks–falling far below analyst and investor expectations.
